What is DuraStat?
DuraStat operates at the intersection of medical technology and surgical precision, focusing on the development of advanced devices for dural repair. By automating suture passage and optimizing needle placement, the company provides a robust solution to incidental durotomy, a complication affecting roughly 10% of spine surgeries. Through strategic partnerships with leading health systems and clinical institutions, DuraStat is effectively reducing the incidence of cerebrospinal fluid leaks, thereby improving patient recovery times and overall surgical outcomes. The company's market position is defined by its commitment to clinical efficiency and the mitigation of high-risk surgical complications.
How much funding has DuraStat raised?
DuraStat has raised a total of $5M across 1 funding round:
Series B
$5M
Series B (2022): $5M, investors not publicly disclosed
Key Investors in DuraStat
Undisclosed Investor
An undisclosed institutional investor participating in the funding round, typically focused on high-growth medical technology and healthcare infrastructure.
Undisclosed Investor
An undisclosed venture capital firm specializing in early-to-growth stage medical device innovation and surgical robotics.
Undisclosed Investor
An undisclosed strategic partner providing capital and industry expertise to accelerate the commercialization of breakthrough surgical tools.
What's next for DuraStat?
With this major enterprise-level funding, DuraStat is poised to scale its operational footprint and expand its commercial reach. The strategic roadmap likely involves deepening its integration within hospital surgical suites and potentially diversifying its product pipeline to address broader orthopedic and neurological repair needs. As the company transitions into this growth phase, the focus will remain on clinical validation and the widespread adoption of its automated repair technology, ensuring that it remains a standard-of-care solution for surgeons worldwide.
See full DuraStat company page
